BCYC

Bicycle Therapeutics
BCYC
Market cap $593M

8.56 USD

+0.35

4.26%

At close Apr 30, 4:00 PM EDT

After hours

8.05

-0.51

5.96%

1 day

4.26%

5 days

-0.81%

1 month

0.82%

3 months

-32.97%

6 months

-64.38%

Year to date

-40.39%

1 year

-63.50%

5 years

-33.13%

10 years

-28.67%

About: Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

Employees: 305

Healthcare Biotechnology

0

Funds holding %

of 7,425 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

2.96% more ownership

Funds ownership: 85.14% [Q3] → 88.1% (+2.96%) [Q4]

8% less funds holding

Funds holding: 105 [Q3] → 97 (-8) [Q4]

17% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 35

25% less funds holding in top 10

Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]

30% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 23

36% less capital invested

Capital invested by funds: $915M [Q3] → $586M (-$329M) [Q4]

42% less call options, than puts

Call options by funds: $148K | Put options by funds: $256K

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$26

204%

upside

Avg. target

$30

247%

upside

High target

$33

286%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Needham Ami Fadia 22% 1-year accuracy 35 / 160 met price target	250%upside $30	Buy Reiterated	9 Apr 2025
Citizens Capital Markets Reni Benjamin 20% 1-year accuracy 8 / 40 met price target	204%upside $26	Market Outperform Reiterated	26 Feb 2025
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 57 / 192 met price target	286%upside $33	Buy Reiterated	26 Feb 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about BCYC published over the past 30 days

Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, announced the presentation of additional human imaging data that validate the potential of MT1-MMP, a tumor antigen overexpressed in many cancers, as a novel target for cancer treatment and demonstrate the positive properties of Bicycle® Radioconjugates (BRC®).

Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025

Bicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This Discounted

Bicycle Therapeutics focuses on novel conjugated targeted therapies for cancer, with promising early results but no clear evidence of superior efficacy yet. Their lead compound, zelenectide pevedotin, shows potential in urothelial carcinoma with a 45% response rate, but more robust studies are needed. Financially, BCYC is well-capitalized with $879.5 million in cash, providing a runway into 2027 despite high operating expenses.

Bicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This Discounted

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on April 1, 2025, the Compensation Committee of the company's Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 32,400 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering.

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, at 12:45 p.m. ET. A live webcast of the fireside chat will be accessible from the Investor section of the company's we.

Bicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced several new governance and key clinical leadership appointments. Felix J. Baker, Ph.D., will succeed Pierre Legault, BAA, MBA, CPA, CA, as chairman of the Bicycle Therapeutics Board of Directors as Mr. Legault and Richard Kender, MBA, will retire f.

Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on March 3, 2025, the Compensation Committee of the company's Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 73,700 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering.

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates. “In 2024, the significant progress across our pipeline and business continued to validate our approach to developing next-generati.

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, Feb. 12, at 10 a.m. ET. A live webcast of the fireside chat will be accessible from the Investor section of the com.

Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on February 3, 2025, the Compensation Committee of the company's Board of Directors granted to 18 new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 117,300 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering.

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bicycle Therapeutics: Trading At Cash, Underwhelming But Not Unsalvageable Data

Bicycle Therapeutics' BT8009 showed promising efficacy and safety in early trials, but mixed results in combination with Keytruda caused significant stock volatility. BT8009 demonstrated a superior safety profile compared to PADCEV, with fewer and milder adverse events due to its shorter half-life and faster elimination. Financially, BCYC is solid with $890 million in cash, providing a runway of 11-12 quarters, though it trades at cash value.

Bicycle Therapeutics: Trading At Cash, Underwhelming But Not Unsalvageable Data

See News Rankings

Charts implemented using Lightweight Charts™